These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 35263436)

  • 1. Dapagliflozin Improves Body Fat Patterning, and Hepatic and Pancreatic Fat in Patients With Type 2 Diabetes in North India.
    Ghosh A; Dutta K; Bhatt SP; Gupta R; Tyagi K; Ansari IA; Venugopal VK; Mahajan H; Pandey RM; Pandey S; Misra A
    J Clin Endocrinol Metab; 2022 May; 107(6):e2267-e2275. PubMed ID: 35263436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
    Bolinder J; Ljunggren Ö; Kullberg J; Johansson L; Wilding J; Langkilde AM; Sugg J; Parikh S
    J Clin Endocrinol Metab; 2012 Mar; 97(3):1020-31. PubMed ID: 22238392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Dapagliflozin and Sitagliptin on Insulin Resistant and Body Fat Distribution in Newly Diagnosed Type 2 Diabetic Patients.
    Sun Y; Yan D; Hao Z; Cui L; Li G
    Med Sci Monit; 2020 Apr; 26():e921891. PubMed ID: 32240122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients.
    Latva-Rasku A; Honka MJ; Kullberg J; Mononen N; Lehtimäki T; Saltevo J; Kirjavainen AK; Saunavaara V; Iozzo P; Johansson L; Oscarsson J; Hannukainen JC; Nuutila P
    Diabetes Care; 2019 May; 42(5):931-937. PubMed ID: 30885955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compensatory changes in energy balance during dapagliflozin treatment in type 2 diabetes mellitus: a randomised double-blind, placebo-controlled, cross-over trial (ENERGIZE)-study protocol.
    Rajeev SP; Sprung VS; Roberts C; Harrold JA; Halford JC; Stancak A; Boyland EJ; Kemp GJ; Cuthbertson DJ; Wilding JP
    BMJ Open; 2017 Jan; 7(1):e013539. PubMed ID: 28132008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of dapagliflozin on obstructive sleep apnea in patients with type 2 diabetes: a preliminary study.
    Tang Y; Sun Q; Bai XY; Zhou YF; Zhou QL; Zhang M
    Nutr Diabetes; 2019 Nov; 9(1):32. PubMed ID: 31685792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease.
    Phrueksotsai S; Pinyopornpanish K; Euathrongchit J; Leerapun A; Phrommintikul A; Buranapin S; Chattipakorn N; Thongsawat S
    J Gastroenterol Hepatol; 2021 Oct; 36(10):2952-2959. PubMed ID: 34129252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High fasting C-peptide levels and insulin resistance in non-lean & non-obese (BMI >19 to < 25 kg/m
    Anoop S; Misra A; Bhatt SP; Gulati S; Mahajan H
    Diabetes Metab Syndr; 2019; 13(1):708-715. PubMed ID: 30641793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial of dapagliflozin and metformin, alone and combined, in overweight women after gestational diabetes mellitus.
    Elkind-Hirsch KE; Seidemann E; Harris R
    Am J Obstet Gynecol MFM; 2020 Aug; 2(3):100139. PubMed ID: 33345876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of dapagliflozin on postprandial lipid metabolism in type 2 diabetes mellitus.
    Burggraaf B; Pouw NMC; Fernández Arroyo S; van Vark-van der Zee LC; van de Geijn GM; Birnie E; Huisbrink J; van der Zwan EM; de Herder WW; Mulder MT; Rensen PCN; Castro Cabezas M
    Eur J Endocrinol; 2022 Apr; 186(5):597-605. PubMed ID: 35312632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION.
    Ekholm E; Hansen L; Johnsson E; Iqbal N; Carlsson B; Chen H; Hirshberg B
    Endocr Pract; 2017 Mar; 23(3):258-265. PubMed ID: 27849380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Aso Y; Kato K; Sakurai S; Kishi H; Shimizu M; Jojima T; Iijima T; Maejima Y; Shimomura K; Usui I
    Int J Clin Pract; 2019 May; 73(5):e13335. PubMed ID: 30810254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients with inadequately controlled type 2 diabetes mellitus.
    Kurinami N; Sugiyama S; Yoshida A; Hieshima K; Miyamoto F; Kajiwara K; Jinnouch K; Jinnouchi T; Jinnouchi H
    Diabetes Res Clin Pract; 2018 Aug; 142():254-263. PubMed ID: 29859912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus Patients.
    Okamoto A; Yokokawa H; Sanada H; Naito T
    Drugs R D; 2016 Sep; 16(3):255-261. PubMed ID: 27333994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes.
    Johansson L; Hockings PD; Johnsson E; Dronamraju N; Maaske J; Garcia-Sanchez R; Wilding JPH
    Diabetes Obes Metab; 2020 Jul; 22(7):1094-1101. PubMed ID: 32072735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysing uric acid levels to assess the effectiveness of dapagliflozin.
    Rajasekar R; Sundaram SM; Raj CP; Poovitha M; Kumar JS
    Clin Nutr ESPEN; 2024 Feb; 59():81-88. PubMed ID: 38220410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats.
    Swe MT; Thongnak L; Jaikumkao K; Pongchaidecha A; Chatsudthipong V; Lungkaphin A
    Clin Sci (Lond); 2019 Dec; 133(23):2415-2430. PubMed ID: 31769484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes.
    Sugiyama S; Jinnouchi H; Kurinami N; Hieshima K; Yoshida A; Jinnouchi K; Nishimura H; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T
    J Atheroscler Thromb; 2018 Jun; 25(6):467-476. PubMed ID: 29225209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dapagliflozin combination therapy in type 2 diabetes mellitus.
    Yacoub T
    Postgrad Med; 2016 Jan; 128(1):124-36. PubMed ID: 26571022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Dapagliflozin on Epicardial Fat Thickness in Patients with Type 2 Diabetes and Obesity.
    Iacobellis G; Gra-Menendez S
    Obesity (Silver Spring); 2020 Jun; 28(6):1068-1074. PubMed ID: 32352644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.